Us Bancorp \De\ Verve Therapeutics, Inc. Transaction History
Us Bancorp \De\
- $77.3 Billion
- Q3 2024
A detailed history of Us Bancorp \De\ transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 18,806 shares of VERV stock, worth $144,806. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,806
Previous 1,086
1631.68%
Holding current value
$144,806
Previous $5,000
1720.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding VERV
# of Institutions
183Shares Held
73.3MCall Options Held
85KPut Options Held
215K-
Alphabet Inc. Mountain View, CA12.3MShares$95.1 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$51 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$38.2 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$32.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$30.8 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $462M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...